50. A process according to any of claims 41 to 49, wherein the compound of formula (VI) is selected from the group consisting of:
6-[3-(4-Fluoro-phenyl)-5-methyl-isoxazol-4-ylmethoxy]-N-(tetrahydro-pyran-4-yl)-nicotinamide;
(1,1-dioxo-1λ^6-thiomorpholin-4-yl)-{6-[3-(4-fluoro-phenyl)-5-methyl-isoxazol-4-ylmethoxy]-pyridin-3-yl}-methanone;
6-[3-(4-Fluoro-phenyl)-5-methyl-isoxazol-4-ylmethoxy]-N-isopropyl-nicotinamide;
N-Cyclopropylmethyl-6-[3-(4-fluoro-phenyl)-5-methyl-isoxazol-4-ylmethoxy]-nicotinamide;
{6-[3-(4-Fluoro-phenyl)-5-methyl-isoxazol-4-ylmethoxy]-pyridin-3-yl}-morpholin-4-yl-methanone; and
6-[3-(4-Fluoro-phenyl)-5-methyl-isoxazol-4-ylmethoxy]-N-(2,2,2-trifluoro-ethyl)-nicotinamide; and pharmaceutically acceptable salts thereof.

51. A process according to any of claims 41 to 50, wherein the compound of formula (VI) is (1,1-dioxo-1λ^6-thiomorpholin-4-yl)-{6-[3-(4-fluoro-phenyl)-5-methyl-isoxazol-4-ylmethoxy]-pyridin-3-yl}-methanone; or pharmaceutically acceptable salts thereof.

52. A process for the preparation of a compound of formula (VI) according to any of claims 41 to 51, comprising the reaction of a compound of formula (II) with a compound of formula (III) to a compound of formula (IV),
followed by the reaction of the compound of formula (IV) to a compound of formula (I),
followed by the reaction of the compound of formula (I) with a compound of formula (V) to a compound of formula (VI);
wherein the compound of formula (II) is 3-(4-Fluoro-phenyl)-5-methyl-isoxazol-4-ylmethanol,
wherein the compound of formula (III) is 6-chloronicotinonitrile,
wherein the compound of formula (IV) is 6-[3-(4-Fluoro-phenyl)-5-methyl-isoxazol-4-ylmethoxy]-nicotinonitrile,
wherein the compound of formula (I) is 6-[3-(4-Fluoro-phenyl)-5-methyl-isoxazol-4-ylmethoxy]-nicotinic acid, or salts thereof;
wherein the compound of formula (V) is thiomorpholine-1,1-dioxide, or salts thereof;
wherein the compound of formula (VI) is (1,1-dioxo-1λ^6-thiomorpholin-4-yl)-{6-[3-(4-fluoro-phenyl)-5-methyl-isoxazol-4-ylmethoxy]-pyridin-3-yl}-methanone, or pharmaceutically acceptable salts thereof.

53. Compounds obtainable by a process according to any of claims 1 to 52.

~~54. The invention as described herein before.~~